Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI.

Tariq U AzamHusam R ShadidPennelope BlakelyPatrick O'HayerHanna BerlinMichael PanPeiyao ZhaoLili ZhaoSubramaniam PennathurRodica Pop-BusuiIzzet AltintasJens TingleffMarius Ahm StauningOve AndersenMaria-Evangelia AdamiNicky SolomonidiMaria TsilikaPinkus Tober-LauEleni ArnaoutoglouVerena KeitelFrank TackeAthanasios ChalkiasSven H LoosenEvangelos J Giamarellos-BourboulisJesper Eugen-OlsenJochen ReiserSalim Salim Hayeknull null

Published in: Journal of the American Society of Nephrology : JASN (2020)

Admission suPAR levels in patients hospitalized for COVID-19 are predictive of in-hospital AKI and the need for dialysis. SuPAR may be a key component of the pathophysiology of AKI in COVID-19.

Keyphrases

coronavirus disease
sars cov
acute kidney injury
emergency department
healthcare
respiratory syndrome coronavirus
end stage renal disease